Trial of Nano-hydroxyapatite-Containing Toothpastes for Relief of Dentin Hypersensitivity

Dentin Sensitivity Clinical Trial

Official title:

Randomized Non-inferiority Trial of Nano-hydroxyapatite-Containing Toothpastes for Relief of Dentin Hypersensitivity

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04590040
• Other study ID #: HSC20190535H
• Status: Completed
• Phase: N/A
• Start date: July 28, 2020
• Est. completion date: March 1, 2023

Study information

• Verified date: July 2023
• Source: The University of Texas Health Science Center at San Antonio
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Subjects will be enrolled into 3 balanced groups each using a different strength toothpaste. Dental hypersensitivity (DHS) will be assessed at study start, midway and study end.

Description:

This study is a double-blind, randomized, placebo-and positive-controlled, stratified parallel group clinical trial. The three groups will be randomly assigned to use one of three test toothpastes having an identical base formulation but containing respectively either 0% nano-hydroxyapatite (HAP) (placebo), 15% nano-HAP or 5% KNO3 (positive control). All dental examinations for data collection will be conducted by the same Clinical Examiner.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 192
• Est. completion date: March 1, 2023
• Est. primary completion date: February 5, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

• Males or females between the age of 20 and 80 years, of any socio-economic status

• Diagnosed as having DHS, i.e. having at least one sensitive tooth with demonstrated cervical erosion/abrasion or gingival recession

• Showing a sensitivity response to both tactile and cold air stimulus delivered by a Yeaple probe and a one-second blast of cold air respectively

• Patients must be reliable, cooperative and of adequate intelligence to read and understand the rating scales and other study instructions

• Patients must be able to read, comprehend, and sign the informed consent form

• The teeth and sites to be tested should be on the buccal/labial surfaces of incisors, canines, premolars or molars where the affected sites are accessible

• Teeth selected for testing should have a plaque index of = 2

Exclusion Criteria:

• The sensitive tooth is associated with concomitant oral pain due to any other condition such as soft-tissue lesions, tooth-ache ascribable to dental caries, tooth fracture, or cracked tooth syndrome, or pain due to other surgical procedures or injuries.

• The sensitive tooth is associated with a periodontal abscess as diagnosed from an X-ray or clinical examination of the tooth

• The sensitive tooth is associated with mobility >1

• The sensitive tooth is associated with gum pain from gingivitis, occlusal trauma, thermal or chemical burns

• Patients having pain from periodontal-related causes but not DHS

• Previous professional desensitizing treatment

• Patients using medication which could interfere with the perception of pain

• Medical histories marked by chronic use of anti-inflammatory agents, daily analgesics, anticonvulsants, antihistamines, antidepressants, sedatives and/or other psychotropic drugs

• Pregnancy or breastfeeding

• Allergies and idiosyncratic responses to toothpaste ingredients

• Eating disorders or conditions associated with vomiting

• Systemic conditions that are etiologic or predisposing to DHS

• Excessive dietary or environmental exposure to acids

• The sensitive tooth was restored in the preceding three months

• The sensitive tooth is an abutment tooth for fixed or removable prostheses

• The sensitive tooth has extensive restoration or restorations extending into the test area

• Patients below 20 years or above 80 years of age

• Smokers

Related Conditions & MeSH terms

• Dentin Sensitivity
• Hypersensitivity

Intervention

Other:
• Placebo
0% nano-HAP toothpaste

Device:
• 15% nano-HAP toothpaste
Toothpaste with identical base formulation as the placebo containing 15% nano-HAP
• 5% KNO3 toothpaste
Toothpaste with identical base formulation as the placebo containing 5% KNO3

Locations

Country	Name	City	State
United States	School of Dentistry, University of Texas Health Science Center	San Antonio	Texas

Sponsors (2)

Lead Sponsor	Collaborator
The University of Texas Health Science Center at San Antonio	Sangi Co., Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement of Cold Air Stimulus	The primary efficacy outcome will be the decrease in cold air stimulus sensitivity (VAS score) from baseline to 8 weeks. Assessment of change in cold air sensitivity will be conducted using air delivered from a standard dental unit air syringe at room temperature (~70°F±3°F)(~21°C±2°C) and a pressure of 60psi (± 5psi). Assessment of sensitivity will be carried out using Visual Analog Scale (VAS). Tooth sensitivity was measured using a Cold Air Stimulus. When being assessed, participants rated their perception of the pain/discomfort experienced when cold air was directed at the exposed root of each tooth by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort.	Week 0 (baseline), 4 weeks and 8 weeks
Secondary	Measurement of Tactile Stimulus	The secondary efficacy outcome will be the increase in tactile stimulus force from baseline to 8 weeks. Assessment of Change in tactile sensitivity will be assessed using the Yeaple Electronic Force Sensing Probe.The explorer tip will be applied perpendicular to the tooth surface and a pressure load applied starting at 10 g and increasing to 80g. The load at which the subject says "yes" will be recorded. (Baseline screening will begin at 30g).	Week 0 (baseline), 4 weeks and 8 weeks